BlackRock’s Albany Molecular Research Inc AMRI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q3 | – | Sell |
-3,684,743
| Closed | -$80M | – | 5125 |
|
|
2017
Q2 | $80M | Sell |
3,684,743
-304,384
| -8% | -$5.52M | ﹤0.01% | 1953 |
|
|
2017
Q1 | $56M | Buy |
3,989,127
+3,984,967
| +95,792% | +$65.3M | ﹤0.01% | 2146 |
|
|
2016
Q4 | $78K | Buy |
4,160
+100
| +2% | +$1.7K | ﹤0.01% | 2709 |
|
|
2016
Q3 | $67K | Hold |
4,060
| – | – | ﹤0.01% | 2829 |
|
|
2016
Q2 | $55K | Buy |
4,060
+2,426
| +148% | +$35.4K | ﹤0.01% | 2893 |
|
|
2016
Q1 | $25K | Buy |
1,634
+1,113
| +214% | +$17.4K | ﹤0.01% | 2754 |
|
|
2015
Q4 | $10K | Hold |
521
| – | – | ﹤0.01% | 2911 |
|
|
2015
Q3 | $9K | Hold |
521
| – | – | ﹤0.01% | 2806 |
|
|
2015
Q2 | $11K | Hold |
521
| – | – | ﹤0.01% | 2757 |
|
|
2015
Q1 | $9K | Hold |
521
| – | – | ﹤0.01% | 2815 |
|
|
2014
Q4 | $8K | Hold |
521
| – | – | ﹤0.01% | 2920 |
|
|
2014
Q3 | $11K | Hold |
521
| – | – | ﹤0.01% | 2700 |
|
|
2014
Q2 | $10K | Sell |
521
-94
| -15% | -$1.59K | ﹤0.01% | 2817 |
|
|
2014
Q1 | $11K | Hold |
615
| – | – | ﹤0.01% | 2681 |
|
|
2013
Q4 | $6K | Hold |
615
| – | – | ﹤0.01% | 3018 |
|
|
2013
Q3 | $8K | Hold |
615
| – | – | ﹤0.01% | 2817 |
|
|
2013
Q2 | $7K | Buy |
+615
| New | +$6.66K | ﹤0.01% | 2905 |
|
Other funds holding AMRI
BlackRock's AMRI Position: Q3 2017 in Review
BlackRock sold out of Albany Molecular Research Inc (AMRI) in Q3 2017, closing a stake of 3,684,743 shares — an estimated $80M sold.
BlackRock first reported a position in AMRI in Q2 2013 and held it in 17 quarters. The position peaked at $80M in Q2 2017. 2 funds tracked by Wall St. Rank hold AMRI as of Q3 2017.
- BlackRock reported no remaining Albany Molecular Research Inc position as of Q3 2017 after selling out during the quarter.
- BlackRock sold 3,684,743 Albany Molecular Research Inc shares in Q3 2017, an estimated $80M.
- BlackRock first reported a position in Albany Molecular Research Inc in Q2 2013 and held it in 17 quarters.
- BlackRock's Albany Molecular Research Inc position peaked at $80M in Q2 2017.
- 2 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q3 2017.
Based on BlackRock's 13F filing for Q3 2017, filed 14 Nov 2017.